Details

Autor(en) / Beteiligte

• Benedetti, L
• Briani, C
• Franciotta, D
• Fazio, R
• Paolasso, I
• Comi, C
• Luigetti, M
• Sabatelli, M
• Giannini, F
• Mancardi, G L
• Schenone, A
• Nobile-Orazio, E
• Cocito, D

Titel

Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature

Ist Teil von

• Journal of neurology, neurosurgery and psychiatry, 2011-03, Vol.82 (3), p.306-308

Ort / Verlag

London: BMJ Publishing Group Ltd

Erscheinungsjahr

2011

Quelle

BMJ Journals Archiv - DFG Nationallizenzen

Beschreibungen/Notizen

• BackgroundA few case reports have shown controversial results of rituximab efficacy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).ObjectiveTo analyse the efficacy of rituximab in a large CIDP cohort.MethodsA retrospective, observational and multicentre study on the use of rituximab in CIDP. 13 Italian CIDP patients were treated with rituximab after the partial or complete lack of efficacy of conventional therapies. Eight patients had co-occurring haematological diseases. Patients who improved by at least two points in standard clinical scales, or who reduced or discontinued the pre-rituximab therapies, were considered as responders.ResultsNine patients (seven with haematological diseases) responded to rituximab: six of them, who were non-responders to conventional therapies, improved clinically, and the other three maintained the improvement that they usually achieved with intravenous immunoglobulin or plasma exchange. Significantly associated with shorter disease duration, rituximab responses started after a median period of 2.0 months (range, 1–6) and lasted for a median period of 1 year (range, 1–5).ConclusionsRituximab seems to be a promising therapeutic choice when it targets both CIDP and co-occurring haematological diseases. Timely post-onset administration of rituximab seems to be associated with better responses.